Skip to main content
. 2013 Sep 12;8(9):e73320. doi: 10.1371/journal.pone.0073320

Table 1. Patients’ demographic and clinical characteristics according to mtDNA haplogroups of the 292 patients of global cohort (first and second cohort combined).

  • HV


  • (n=129)

  • U


  • (n=71)

  • No R


  • (n=46)

  • Total


  • Non JT


  • (n=246)

  • JT


  • (n=46)

  • p


  • JT vs Non JT

Gender male -n (%) 90 (69.8) 49 (69.0) 28 (60.9) 167 (67.9) 27 (58.7) 0.24
Age - median years (p 25-75) 61 (50-71) 61 (51-73) 61 (45-71) 61 (49-71) 57 (49-70) 0.42
Diabetes Mellitus -n (%) 42 (32.6) 22 (31.0) 10 (21.7) 74 (30.1) 10 (21.7) 0.29
COPD -n (%) 18 (14.0) 9 (12.7) 4 (8.7) 31 (12.6) 8 (17.4) 0.35
Ischemic heart disease -n (%) 15 (11.6) 7 (9.9) 5 (10.9) 27 (11.0) 3 (6.5) 0.44
Site of infection 0.51
- Respiratory -n (%) 78 (60.5) 43 (60.6) 23 (50.0) 144 (58.5) 23 (50.0)
- Abdominal -n (%) 30 (23.3) 18 (25.3) 16 (34.8) 65 (26.4) 15 (32.6)
- Neurological -n (%) 3 (2.3) 1 (1.4) 1 (2.2) 5 (2.0) 1 (2.2)
- Urinary -n (%) 6 (4.6) 3 (4.2) 2 (4.3) 11 (4.5) 4 (8.7)
- Skin -n (%) 4 (3.1) 2 (2.8)
  • 4 (8.7)


  • )

  • 9 (3.7)


  • )

3 (6.5)
- Endocarditis -n (%) 7 (5.4) 4 (5.6) 0 (0) 11 (4.5) 0 (0)
- Osteomyelitis -n (%) 1 (0.8) 0 (0) 0 (0) 1 (0.4) 0 (0)
Microorganism responsibles
- Unkwon -n (%) 66 (51.2) 37 (52.1) 23 (50.0) 126 (51.2) 20 (43.5) 0.42
- Gram-positive- n (%) 30 (23.3) 19 (26.8) 11 (23.9) 60 (24.4) 14 (30.4) 0.46
- Gram-negative- n (%) 31 (24.0) 16 (22.5) 12 (26.1) 59 (24.1) 12 (26.1) 0.85
- Fungii- n (%) 5 (3.9) 2 (2.8) 1 (2.2) 8 (3.3) 0 (0) 0.36
- Anaerobe- n (%) 1 (0.8) 0 (0) 1 (2.2) 2 (0.8) 1 (2.2) 0.40
Bloodstream infection 21 (16.3) 7 (9.9) 10 (21.7) 38 (15.4) 9 (19.6) 0.51
Empiric antimicrobial treatment adequate 0.58
- Unkown due to negative cultures- n (%) 66 (51.2) 36 (50.7) 23 (50.0) 125 (50.8) 20 (43.5)
- Adequate -n (%) 49 (38.0) 30 (42.3) 22 (47.8) 101 (41.1) 20 (43.5)
- Unkown due to antigenuria diagnosis- n (%) 3 (2.3) 2 (2.8) 1 (2.2) 6 (2.4) 2 (4.3)
- Inadequate- n (%) 11 (8.5) 3 (4.2) 0 (0) 14 (5.7) 4 (8.7)
Betalactamic more aminoglycoside- n (%) 28 (21.7) 15 (21.1) 10 (21.7) 53 (21.5) 11 (23.9) 0.70
Betalactamic more quinolone- n (%) 61 (47.3) 40 (56.3) 27 (58.7) 128 (52.0) 22 (47.8) 0.63
Septic shock- n (%) 110 (85.3) 60 (84.5) 40 (87.0) 210 (85.4) 41 (89.1) 0.65
PaO2/FIO2 ratio - median (p 25-75) 180 (121-257) 150 (86-250) 168 (93-328) 175 (106-260) 161 (104-252) 0.51
Creatinine (mg/dl) - median (p 25-75) 1.40 (0.85-2.50) 1.40 (0.90-2.00) 1.40 (0.70-2.60) 1.40 (0.90-2.35) 1.55 (0.97-2.85) 0.47
Bilirubin (mg/dl) - median (p 25-75) 1.00 (0.57-2.10) 0.90 (0.60-1.57) 0.85 (0.40-1.97) 0.94 (0.56-1.90) 1.30 (0.47-1.50) 0.56
Leukocytes -median*103/mm3 (p 25-75) 15.2 (9.3-20.3) 11.9 (6.1-22.0) 12.8 (8.6-15.7) 14.0 (8.7-20.0) 15.9 (11.5-25.7) 0.89
Lactic acid - median mmol/L (p 25-75) 2.30 (1.20-4.55) 2.60 (1.40-4.20) 2.10 (0.90-4.70) 2.26 (1.20-4.40) 2.60 (1.25-4.05) 0.77
Platelets - median*103/mm3 (p 25-75) 176 (99-238) 192 (83-317) 196 (87-245) 179 (97-255) 145 (96-221) 0.17
INR - median (p 25-75) 1.40 (1.10-1.69) 1.29 (1.11-1.56) 1.33 (1.12-1.52) 1.33 (1.11-1.59) 1.24 (1.14-1.51) 0.56
aPTT - median seconds (p 25-75) 33 (28-43) 35 (29-41) 34 (28-50) 33 (28-43) 31 (27-42) 0.86
Interleukin-6 (pg/ml) - median (p 25-75) 110 (37-984) 171 (42-1070) 301 (45-1075) 161 (42-1012) 314 (32-1010) 0.59
SOFA score - median (p 25-75) 9 (7-12) 10 (8-12) 9 (7-12) 9 (7-12) 9 (7-12) 0.84
APACHE-II score - median (p 25-75) 20 (16-26) 20 (15-24) 21 (16-23) 20 (16-25) 20 (15-23) 0.52
Survivors at 30 days- n (%) 83 (64.3) 45 (63.4) 28 (60.9) 156 (63.4) 38 (82.6) 0.007
Survivors at 6 months- n (%) 69 (53.5) 36 (50.7) 24 (52.2) 129 (52.4) 35 (76.1) 0.002

COPD = chronic obstructive pulmonary disease; PaO2/FIO2 = pressure of arterial oxygen/fraction inspired oxygen; INR = International normalized ratio; aPTT = Activated partial thromboplastin time; SOFA = Sepsis-related Organ Failure Assessment; APACHE-II = Acute Physiology and Chronic Health Evaluation-II score. Data are presented as number (percentage) or median (interquartile range)